Intravitreal injections of antibody-based biologics targeting vascular endothelial growth factor (VEGF) are highly effective and have markedly decreased the risk of visual impairment associated with prevalent retinal diseases, such as neovascular age-related macular degeneration and diabetes macular oedema. Th...
Harnessing the power of the human immune system is steadily gaining recognition for its importance in the treatment of cancer.13BsAbs can simultaneously bind to two different antigens.14The most widely used BsAb is a bispecific T cell engager (BiTE), with one arm targeting CD3 on T cells and...
A literature search was conducted through November 30, 2021 on PubMed, Medline, Google Scholar, and associated digital platforms with the following keywords: wet macular degeneration, age-related macular degeneration, therapy, VEGF-A, VEGF-C, VEGF-D, integrins, Tie2/Ang2, and tyrosine kinase ...
when the vitreous and the macular area of the retina are tightly conjugated, macular edema can be greatly promoted[94]. Posterior vitreous detachment occurs when the posterior cortex of the vitreous separates from the internal limiting membrane for several ...
The Company is also evaluating a topical ophthalmic formulation of its second-generation clinical-stage candidate, SBT-272, for dry age-related macular degeneration. The Company has a deep pipeline of novel compounds under evaluation for rare neurological and cardiac disease indications following ...
Anti-VEGF-A therapy will never completely go away for the treatment of neovascular age-related macular degeneration, but new therapies that improve the efficacy and durability of treatment are needed to help bri...
Bruce Spivey, MD, MS, MEd, vice president and OF representative to IAPB (previously served as secretary-treasurer. New board member include: Brent Saunders is the CEO and chairman of the Board of Directors of Bausch + Lomb. He joins the Board with over 25 years of experience and leadershi...
Curr Med Res Opin. 2010;26(8):2011−2023. 20. Lien EL, Hammond BR. Nutritional influences on visual development and function. Prog Retin Eye Res. 2011;30(3):188−203. 21. Wong IY, Koo SC, Chan CW. Prevention of age-related macular degeneration. Int Ophthalmol. 2011;31(1):73...
The first clinical trials with RNAi therapeutics target the VEGF pathway for the wet form of AMD and the RSV genome for treatment of RSV infection; in both cases the initial approach is direct administration of the RNAi therapeutic in a saline formulation. In both these cases, highly validated...
Age-related macular degeneration (AMD) is a common cause of blindness in older individuals. To accelerate the understanding of AMD biology and help design new therapies, we executed a collaborative genome-wide association study, including >17,100 advanced AMD cases and >60,000 controls of European...